FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
22/06/2026 11:54
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports June 22 (Reuters) - The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio RGNX.O, the Wall Street Journal reported on Monday.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Diti Pujara)